申请人:Hoffman-LaRoche Inc.
公开号:US05204482A1
公开(公告)日:1993-04-20
Ethylenediamine monoamides of the formula R--CO--NH--CH.sub.2 --CH.sub.2 --NH.sub.2 I wherein R is one of groups ##STR1## in which R.sup.1 is phenyl, monohalophenyl, monolower-alkylphenyl, monolower-alkoxyphenyl, monotrifluoromethylphenyl, monocyanophenyl or monaryl-lower-alkoxyphenyl, dihalophenyl, furyl, thienyl or monohalothienyl, R.sup.2 is hydrogen, halogen or amino, R.sup.3, R.sup.5 and R.sup.7 each are phenyl, monohalophenyl, dihalophenyl, thienyl, furyl or monohalofuryl, R.sup.4 and R.sup.6 each are hydrogen or amino and R.sup.8 is hydrogen or lower-alkyl, as well as their pharmaceutically usable acid addition salts are disclosed. The compounds have monoamine oxidase inhibiting properties with low toxicity and are useful for the treatment of depressive states and cognitive disorders.
本发明揭示了式为R--CO--NH--CH.sub.2 --CH.sub.2 --NH.sub.2 I的乙二胺单酰胺,其中R是以下组之一##STR1##其中R.sup.1是苯基,单卤苯基,单低烷基苯基,单低烷氧基苯基,单三氟甲基苯基,单氰基苯基或单芳基-低烷氧基苯基,二卤苯基,呋喃基,噻吩基或单卤噻吩基,R.sup.2是氢,卤素或氨基,R.sup.3,R.sup.5和R.sup.7分别是苯基,单卤苯基,二卤苯基,噻吩基,呋喃基或单卤呋喃基,R.sup.4和R.sup.6分别是氢或氨基,R.sup.8是氢或低烷基,以及它们的药学可用的酸加盐。这些化合物具有低毒性的单胺氧化酶抑制作用,并可用于治疗抑郁症和认知障碍。